Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

• Status: Not yet recruiting
• Trial end date: 2025-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the present study is to study the effect of baricitinib administration on outcome of participants with moderate and severe traumatic intracerebral hemorrhage/contusions. A multi-center randomized control trial will be conducted. Participants with a radiological diagnosis of traumatic intracerebral hemorrhage/contusions and an initial GCS score of 5-12 will be screened and enrolled in the first 24 hours after traumatic brain injury.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tang-Du Hospital

Criteria

Inclusion Criteria:

1. Age 18 years older and younger than 80 years old.

2. Definite history of traumatic brain injury.

3. Admission within≤24 hours after the traumatic brain injury.

4. CT scans demonstrate intracerebral hemorrhage/contusions with and without extracerebral hemorrhage (epi- and sub- dural hemorrhage)

5. GCS score of 5 or greater and no more than 12 at time of enrollment.

6. Closed head injury.

7. Admission without infections

8. Signed and dated informed consent by the subject, legally authorized representative, or surrogate obtained.

Exclusion Criteria:

1. Time of head injury cannot be reliably assessed.

2. Subjects is considered a candidate for immediate surgical intervention because of severe extracranial injury.

3. Open head injury.

4. Pregnancy or parturition within previous 30 days or active lactation.

5. Use of Janus kinase inhibitors (baricinitib,abroctinib, AG490 and etc.)

6. Pre-traumatic dementia or disability.

7. With severe liver, kidney disease, or malignancy, life expectancy is less than 14 days.

8. Severe pulmonary infection.

9. Severe or acute heart failure.

10. Severe infections within previous 30 days.

11. History of myocardial infarction.

12. Known sensitivity to baricinitib.

13. Severe decreases in neutrophil, lymphocyte and platelet counts, severe decrease in hemoglobin.

14. Severe liver and kidney dysfunction.

15. Currently participating in other interventional clinical trials.